AstraZeneca (AZN) Reports Positive Phase IIa Results from the EPICCURE Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
AstraZeneca (AZN) Has Supplied Two Billion Doses of COVID-19 Vaccine in 11 Months
November 16, 2021 6:00 AM ESTAstraZeneca (NASDAQ: AZN) and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the last 11 months.
Approximately two-thirds of these have gone to low- and lower-middle-income countries, including more than 175 million doses delivered to 130 countries through the COVAX Facility.
This milestone comes just over 18 months after AstraZeneca and Oxford University formed their landmark partnership for the global development and distribution... More
UBS Reiterates Buy Rating on AstraZeneca (AZN:LN) (AZN)
November 15, 2021 4:45 AM ESTUBS analyst Michael Leuchten reiterated a Buy rating and GBP100.00 price target on AstraZeneca (AZN:LN) (NASDAQ: AZN).
... MoreIncreasing unusual put option volume: WEN EVGO MQ MAPS SNDL AZN SFT BLNK
November 12, 2021 10:04 AM ESTIncreasing unusual put option volume: WEN EVGO MQ MAPS SNDL AZN SFT BLNK
... MoreAstraZeneca (AZN) Reports Q3 Core EPS of $1.08, Revenues of $9.87B
November 12, 2021 5:30 AM ESTAstraZeneca (NASDAQ: AZN) reported Q3 Core EPS of $1.08. Revenue for the quarter came in at $9.87 billion versus the consensus estimate of $9.87 billion.
GUIDANCE:
AstraZeneca sees FY2021 Core EPS of $5.05-$5.40, versus the consensus of $3.27.
For earnings history and earnings-related data on AstraZeneca (AZN) click here.
... MoreAstraZeneca starts to make modest profit from COVID-19 vaccine
November 12, 2021 2:33 AM ESTBy Pushkala Aripaka and Ludwig Burger
(Reuters) - AstraZeneca said it would begin to earn a modest profit from its coronavirus vaccine as the world learns to live with the virus and the drugmaker is in talks with several countries about new orders for delivery next year.
AstraZeneca made a commitment to sell the shot developed with Oxford University at cost during the pandemic and in a press conference on Friday said low-income nations would continue to receive the vaccine on a no-profit basis, while a post-pandemic commercial approach would apply to other new orders even as... More
